{"title":"很多热情,很多问题。","authors":"Michael D Dalzell","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Value-based benefit design is all the rage, but applying it to biologics is complicated. Several issues must be addressed if VBBD is to rule this frontier.</p>","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 2","pages":"10-4"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138390/pdf/bth08_2p010.pdf","citationCount":"0","resultStr":"{\"title\":\"Lots of enthusiasm, lots of questions.\",\"authors\":\"Michael D Dalzell\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Value-based benefit design is all the rage, but applying it to biologics is complicated. Several issues must be addressed if VBBD is to rule this frontier.</p>\",\"PeriodicalId\":89534,\"journal\":{\"name\":\"Biotechnology healthcare\",\"volume\":\"8 2\",\"pages\":\"10-4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138390/pdf/bth08_2p010.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biotechnology healthcare\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology healthcare","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Value-based benefit design is all the rage, but applying it to biologics is complicated. Several issues must be addressed if VBBD is to rule this frontier.